Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine
Neonorm™ Calf, one of Jaguar’s lead non-prescription products, has been formulated and clinically tested to help proactively retain fluid in dairy calves and reduce the severity of diarrhea—aiding the animals in avoiding debilitating, dangerous levels of dehydration associated with scours. The powder form of the product allows for ease of administration for entire herd management.
This double-blind, randomized study involved 40 newborn Holstein bull calves and compared the prophylactic use of Neonorm™ against a placebo. Treatment administration was performed twice daily for 14 days starting on the first feeding after colostrum administration. The calves were kept for an additional 10 days after the final treatment administration for clinical observation and sample collection. Calves were housed in individual pens and feeding was restricted to saleable whole milk. Data regarding fecal dry matter were used to measure water loss due to secretory diarrhea.
The study results show that calves under prophylactic administration of Neonorm™ had significantly lower water content in fecal samples at multiple measurement points, lower incidence of diarrhea, and had fewer fluid therapy interventions.
Fecal scoring, which was conducted daily during the study period, indicated a significantly lower incidence of diarrhea among Neonorm™-treated calves on most treatment days than among calves in the placebo group. The study also assessed the incidence of diarrhea from days 1 to 25 of life. Calves in the Neonorm™-treated group experienced a highly significant reduction in the incidence of diarrhea during this period compared to those in the placebo group.
Dehydration was assessed twice daily for all calves in the study. Results showed that severe dehydration requiring the administration of intravenous (“IV”) fluid therapy was reduced by approximately 50% in the Neonorm™-treated calves. Moreover, overall rescue therapy, requiring either oral or IV fluid administration, for both severe and moderate dehydration, was significantly reduced in the Neonorm™-treated animals.
The study results complement the results of a prior study, also
conducted by Jaguar in association with
“The results appear to support the potential prophylactic benefits of an
easy-to-administer powder formulation of Neonorm™ on reducing
the incidence and severity of diarrhea and associated fluid loss,
herd-wide, in calves,” commented Dr.
As Jaguar announced this past July, the Company has entered into
negotiations for a potential exclusive distribution relationship for
Neonorm™ for dairy cattle and pigs in the Chinese marketplace
Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Jaguar intends to develop species-specific formulations of Neonorm™ in six additional target species.
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the potential
prophylactic benefits of a powder formulation of Neonorm™ on
reducing the incidence and severity of diarrhea and associated fluid
loss, herd-wide, in calves, a potential exclusive distribution
relationship for dairy cattle and pigs in the Chinese marketplace
between Jaguar and the
1Diarrhoea or Scour. Retrieved
KCSA Strategic Communications
Garth Russell, 212-896-1250